Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSYPNW)

• Drug Name: Ranibizumab Drug Info
• Synonyms: Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia)

Indication

Disease Entry	ICD 11	Status	REF
Central retinal vein occlusion with macular edema		Approved	[1]
Diabetic macular edema	9B71.02	Approved	[2]
Diabetic retinopathy	9B71.0	Approved	[3]
Exudative age-related macular degeneration	9B78.3Z	Approved	[4]
Hereditary hemorrhagic telangiectasia	LA90.00	Approved	[5]

• Cross-matching ID: TTD Drug ID: DMSYPNW

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor A (VEGFA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[7]
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[8]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[9]
Bevacizumab	DMSD1UN	Adenocarcinoma	2D40	Approved	[10]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[11]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[12]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[13]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[14]
Abicipar pegol	DM59OJ2	Diabetic macular edema	9B71.02	Phase 2	[15]
MP0250	DMR3VCY	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Not Available	[6]

References

• [1] A review of neovascular glaucoma. Etiopathogenesis and treatment. Rom J Ophthalmol. 2021 Oct-Dec;65(4):315-329.
• [2] Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol. 2023 Mar-Apr;68(2):147-174.
• [3] Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2018 Oct 1;136(10):1138-1148.
• [4] Age-related macular degeneration: anti-vascular endothelial growth factor treatment. BMJ Clin Evid. 2016 Feb 24;2016:0701.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6779).
• [6] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [9] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [10] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [11] Clinical pipeline report, company report or official report of Genentech (2009).
• [12] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [13] Bispecific antibodies and their applications
• [14] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)